Merck & Company Inc (MRK)

86.73
+0.61(+0.71%)
  • Volume:
    3,680,997
  • Day's Range:
    86.02 - 87.21
  • 52 wk Range:
    71.50 - 95.72

MRK Overview

Prev. Close
86.12
Day's Range
86.02-87.21
Revenue
57.17B
Open
86.79
52 wk Range
71.5-95.72
EPS
6.56
Volume
3,680,997
Market Cap
219.38B
Dividend (Yield)
2.76
(3.20%)
Average Vol. (3m)
8,165,711
P/E Ratio
13.26
Beta
0.336
1-Year Change
5.8%
Shares Outstanding
2,533,279,845
Next Earnings Date
Oct 27, 2022
What is your sentiment on Merck&Co?
or
Vote to see community's results!

Merck & Company Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Merck & Company Inc Analysis

Merck & Company Inc Company Profile

Merck & Company Inc Company Profile

Employees
67500

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species.

Read More

Analyst Price Target

Average97.27 (+12.12% Upside)
High115
Low76
Price86.76
No. of Analysts22
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuyNeutralBuy
Technical IndicatorsBuySellSellBuyStrong Buy
SummaryStrong BuyNeutralNeutralNeutralStrong Buy
  • cross 52 week highs $100 very big upside merck
    0
    • Good write up in WSJ today. Should be up.
      0
      • 🚀🚀🚀🚀🚀🚀🚀
        1
        • This will be 120+ soon
          4
          • you are in outer space
            0
          • help you need to figure it out on your own listening to mrons and thier baseless predictions how is that working for you
            0
          • NY Brokers Stock ExchangeAs soon as they start selling their covid drug in USA
            0
        • ma e' sui massimi da sempre? che t.p. si puo' immaginare a questo punto ?
          2
          • 🚀🚀🚀🚀🚀🚀🚀🌜
            0
            • Good, even great reasults in first quater of 2022.Let's hope to go back to 86-87 territory
              0
              • The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention.
                0
                • The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.
                  0
                  • The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.
                    0